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tal anastomosis 5 days after implantation. Furthermore,
preliminary results in a mouse knockout model demon-
strated that the absence of ApoJ increased the amount of
IH after arterial injury, supporting a role for ApoJ in mod-
ulating the response to vascular wall injury.4
ApoJ was first shown to aggregate sertoli cells in
vitro.5 It is an 80-kDa heterodimeric glycoprotein consist-
ing of two subunits connected by five disulfide bonds.6
ApoJ is found in many different pathologic processes7 and
is expressed in many tissues, including the arterial wall and
heart. In addition, tissues that do not normally express
ApoJ can be made to do so in various physiologic condi-
tions. Recently, it was localized to VSMCs in the athero-
sclerotic aorta,8,9 and it is produced by VSMCs in vitro.10
However, the molecular mechanism of action of ApoJ has
not been determined.
The role of ApoJ in IH has not been characterized.
However, several observations are pertinent to vascular
wall biology. ApoJ is upregulated at times of cell stress and
tissue injury.8,9,11 In vitro studies indicate ApoJ is a cyto-
protectant against oxidative stress,12 provides resistance 
to apoptotic cell death,13 and decreases complement-
Anastomotic intimal hyperplasia (IH) accounts for the
majority of morbidity associated with prosthetic arterial
grafting.1 The processes of tissue injury and remodeling
play key roles in this pathologic entity. Recently, the gene
for apolipoprotein J (ApoJ) was found upregulated at the
distal anastomosis of a canine carotid polytetrafluoroethyl-
ene interposition graft model with messenger RNA
(mRNA) differential display.2,3 Additionally, ApoJ was iso-
lated to vascular smooth muscle cells (VSMCs) at the dis-
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Purpose: Apolipoprotein J (ApoJ) is expressed during tissue injury and remodeling and has been implicated in vascular
smooth muscle cell (VSMC) differentiation. Recently, the gene for ApoJ was identified as upregulated in distal anas-
tomotic intimal hyperplasia after prosthetic arterial grafting. In this study we investigate the effect of ApoJ on VSMC
migration, adhesion, proliferation, and gene expression.
Methods: To study the effect of ApoJ on cell migration, we used a microchemotaxis chamber with an intervening 8-µm
pore semipermeable polycarbonate membrane. Assays were performed with ApoJ alone (1-50 µg/mL) or in combina-
tion with platelet-derived growth factor homodimer bb (PDGF-bb; 10 ng/mL) or 2% fetal bovine serum (FBS; n = 8)
in the lower wells. The influence of extracellular matrix interactions on ApoJ and chemotaxis was studied in a similar
way, except membranes were collagen coated. Furthermore, cells were exposed to ApoJ 15 minutes before or after seed-
ing on the coated membrane (n = 10). The influence of ApoJ on cell adhesion to collagen was assessed with cell expo-
sure to ApoJ 15 minutes before or after seeding on a collagen-coated membrane (n = 10). Migration and adhesion were
quantified by counting the number of cells per three independent high-power fields with light microscopy. The effect
of ApoJ in 0.4% FBS with or without PDGF-bb on VSMC proliferation (n = 12) was assessed by means of [Methyl-
3H] thymidine incorporation. The transcriptional profile of VSMCs in 2% FBS exposed to ApoJ and a control for 24
hours was analyzed with an oligonucleotide microarray containing 12,560 genes.
Results: ApoJ alone was not chemotactic for VSMCs. Without collagen, ApoJ decreased the migration of VSMCs
toward 2% FBS by 96% or more starting at 10 µg/mL (P < .05) and toward PDGF-bb by 60.9% or more starting at
25 µg/mL (P < .05) compared with the control. When collagen was introduced, ApoJ (25 µg/mL) decreased migra-
tion toward 2% FBS by 64% (P < .01) and toward PDGF-bb by 67.5% (P < .01) and decreased adhesion by 26.8% (P
< .01) only when VSMCs in solution were exposed to ApoJ before placement on collagen. ApoJ did not induce VSMC
proliferation. ApoJ alone decreased VSMC thymidine incorporation by 41.1% at 25 µg/mL (P < .05). ApoJ decreased
thymidine incorporation of PDGF-bb stimulated VSMCs by 42.8% at 50 µg/mL (P < .05). Interleukin-8 and endothe-
lin-1 were demonstrated by means of the microarray to be differentially expressed more than twofold in VSMCs that
were exposed to ApoJ.
Conclusion: ApoJ is a potent inhibitor of VSMC migration, adhesion, and proliferation. Its genetic targets are linked
to cell senescence and differentiation. Therefore, ApoJ may play a role, in part, in modulating the VSMC response to
injury. (J Vasc Surg 2001;34:716-23.)
mediated cell lysis.14 In addition, ApoJ is universally seen
in areas of active tissue remodeling. The reason for this
upregulation and its functional role is unknown. These
findings suggest that it may be an acute phase reactant,
although evidence is inconclusive. Furthermore, ApoJ
may be involved in VSMC differentiation and senes-
cence.15 In vitro studies have shown ApoJ transforms
VSMC morphology to a nonproliferating differentiated
state.10,15,16 Finally, part of the key to its action(s) on the
cell may be related to its potent cell aggregating proper-
ties.5 ApoJ may be induced to promote cell-cell and cell-
substratum interactions that are disturbed in settings of
tissue injury. Promoting cell-cell contact may enhance cell
survival by providing a mechanism for the sharing of lim-
ited nutrients and intracellular signals.17
The purpose of this study was to characterize the effect
of ApoJ on human aortic VSMC migration, adhesion, and
proliferation. Furthermore, the transcriptional profile of
VSMCs exposed to ApoJ was analyzed to determine the
transcriptional control of cellular function of ApoJ.
MATERIAL AND METHODS
General materials. Human aortic VSMCs were
obtained from ATCC (Manassas, Va). High glucose
Dulbeco’s modified eagle (DMEM) medium with 
2 mmol/L L-glutamine, phosphate-buffered saline 
(PBS), penicillin/streptomycin/amphotericin B, N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic (HEPES)
buffer, fetal bovine serum (FBS), and 0.05% trypsin/
ethylenediamine tetraacetic acid (EDTA) were obtained
from Life Technologies (Rockville, Md). Human ApoJ
was obtained from Quidel (San Diego, Calif). Human
recombinant platelet-derived growth factor homodimer BB
(PDGF-bb) and rat tail collagen type I were obtained from
Upstate Biotechnology (Lake Placid, NY). [Methyl-3H]
thymidine was obtained from Amersham Pharmacia
(Piscataway, NJ).
Cell culture. VSMCs were grown in DMEM supple-
mented with penicillin/streptomycin/amphotericin B, 1
mol/L HEPES buffer, 3.7 g/L NaHCO3, and 10% FBS.
Cells were incubated in humidified 95% O2, 5% CO2 at
37°C, harvested near confluence with trypsin/EDTA, and
reseeded 1 to 3. Experiments used low cell passage (3-6).
For migration assays, subconfluent VSMCs were starved for
24 hours in low serum (0.4% FBS) DMEM (LSM).18 For
adhesion assays, VSMCs were starved for 24 hours in serum-
free (0% FBS) DMEM (SFM). SFM was chosen for starva-
tion before adhesion assays to remove any influence that the
serum would have on adhesion molecule expression.
Cell migration. A 48-well microchemotaxis chamber
with an intervening 8-µm pore polycarbonate membrane
(Neuroprobe; Gaithersburg, Md) separating the upper
and lower wells was used as a means of assessing the effect
of ApoJ on VSMC migration. Cells starved in LSM were
resuspended only in SFM. ApoJ was used at concentra-
tions of 1, 5, 10, 25, and 50 µg/mL in the lower cham-
ber. The choice of these concentrations has been
described.12 PDGF-bb was used at 10 ng/mL. ApoJ alone
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or with PDGF-bb or 2% FBS was added only to the lower
chambers, and the membrane was applied. Two percent
FBS or PDGF-bb in the lower chamber alone served as a
control. Higher concentrations of FBS were not used,
because extensive cell deposition on the membrane made
quantifying migration difficult. The upper wells were
seeded with 2.5-by-104 cells in SFM per well. Assays were
conducted in 4 hours at 37°C. The membrane’s upper
side was rinsed in PBS and wiped. The membrane was
fixed in 70% ethanol and stained in hematoxylin.
Migration was assessed by counting the number of cells
per three independent high-power fields (HPFs) with
light microscopy. Chemotaxis was expressed as the mean
number of cells migrated ± SE.
Cell adhesion. A 24-well Transwell 8-µm pore size
polycarbonate membrane cell culture chamber (Corning;
Corning, NY) was used as a means of assessing the effect
of ApoJ on VSMC adhesion. Cells starved in SFM were
washed in PBS and harvested with trypsin/EDTA. The
upper side of the membrane was coated with 10 µg/mL
collagen type I to promote cell adhesion. Cells were
divided into aliquots of 1 × 104 cells resuspended in SFM.
The first aspect of this assay exposed recently trypsinized
cells in SFM to ApoJ for 15 minutes before placement on
the coated membrane. The second aspect allowed cells to
attach to the coated membrane for 15 minutes before
exposure to ApoJ. Cells in SFM alone served as a control.
Chambers were incubated for 1 hour at 37°C. This time
was chosen to study the early interactions between ApoJ
and VSMCs because the clustering effect of ApoJ on
VSMCs is immediate. With an increase of the assay time,
the abundance of cell-matrix interactions with time would
overcome the potential competing cell-cell interactions of
ApoJ and might deplete the effects of ApoJ. Next, the
membrane’s upper portion was rinsed, fixed, and stained
as aforementioned. Adhesion was assessed by counting the
number of cells per three independent HPFs. VSMC
adhesion was expressed as the mean number of cells
bound to the membrane ± SE.
Influence of cell-matrix interactions on chemotaxis.
To determine the effect of ApoJ on cell migration toward
growth factor in the presence of an extracellular matrix, we
performed assays similar to the adhesion assay by using the
Transwell migration chamber with 8-µm pore size colla-
gen-coated membrane. Two percent FBS or PDGF-bb (10
ng/mL) was placed in the lower wells. Cells starved in
LSM and resuspended in SFM (5 × 104 cells) were exposed
to ApoJ before or after placement on the coated membrane
as described for adhesion. Stimulants alone served as a con-
trol. Membranes were incubated, processed, and analyzed
as described for migration.
Cell proliferation. [Methyl-3H]thymidine incorpo-
ration assay was used as a means of assessing the effect of
ApoJ on cell proliferation. A total of 2500 cells/well were
placed in a 96-well plate and incubated overnight in
DMEM plus 10% FBS to facilitate attachment to the well
bottom. Cells were starved in LSM for 48 hours and then
cultured for 24 hours with varying concentrations of ApoJ
in 0.4% FBS with or without PDGF-bb (10 ng/mL).
DMEM plus 0.4% FBS or PDGF-bb alone served as a con-
trol. Cells were originally placed in ApoJ with 0.4% FBS to
see whether ApoJ alone stimulated proliferation. To main-
tain cell attachment to the plate, we needed 0.4% FBS.
Labeling and processing of cells were performed as
described.19 Radioactivity was quantitated by means of
liquid scintillation counting. [Methyl-3H]thymidine
incorporation was expressed as the mean counts per
minute ± the SE. The intensity of the signal was confirmed
with positive and negative controls.
Cell viability. We used the trypan blue exclusion
method to determine the viability of ApoJ-exposed
VSMCs. Cells were seeded into a 24-well plate at 1-by-104
cells/well with DMEM plus 10% FBS. A total of 50
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µg/mL of ApoJ were added to the wells. Cells in DMEM
plus 10% FBS alone served as a control. Similar studies
were done in 0.4% FBS. Cells were incubated for 72 hours
at 37°C and visually inspected for the 3 days to check for
cell overgrowth or death. On day 3, each well was washed
with PBS, trypsinized, and resuspended in DMEM plus
0.4% trypan blue. The number of cells with or without dye
incorporation was counted with a hemocytometer. Cell
viability was expressed as the mean number of cells with-
out dye incorporation divided by the total number of cells.
Differential expression. To determine the transcrip-
tional profile of VSMCs exposed to ApoJ, we chose the
Affymetrix Human Genome U95A gene chip expression
analysis probe array, an oligonucleotide microarray
(Affymetrix, Santa Clara, Calif). It represents approxi-
mately 12,560 sequences that have been characterized in
terms of function or disease association from the UniGene
database. The sensitivity of the assay was the detection of
one transcript in 100,000. Further information can be
obtained from www.affymetrix.com.
VSMCs were starved for 48 hours in SFM, trypsinized,
resuspended in DMEM plus 2% FBS with or without ApoJ
(50 µg/mL) in aliquots of 1 × 106 cells/25 cm2, and incu-
bated for 24 hours at 37°C. RNA was extracted with the
Qiagen RNeasy minikit (Valencia, Calif), following the
manufacturer’s recommendations. RNA from ApoJ and
control samples was labeled, fragmented, hybridized, and
scanned20 at the Gene Array Technology Center at
Brigham and Women’s Hospital (Boston, Mass). Data
were analyzed with GeneChip 3.1 expression analysis soft-
ware (Affymetrix) and imported into Microsoft Excel.
Significant differential expression had to meet certain
inclusion/exclusion criteria within the analysis software.21
Furthermore, hybridization had to be present in both sam-
ples, and the fold change had to be more than 2.0.
Statistical analysis. We used the one-way analysis of
variance with post hoc testing with the Tukey/Kramer
Honestly Significant Difference Test for statistical analysis.
A P value less than .05 was considered to be significant.
RESULTS
Combined effect of apolipoprotein J and individ-
ual growth factors on chemotaxis. Initially, experiments
were designed as a means of evaluating whether ApoJ was
chemotactic for VSMCs. No chemotactic effect of ApoJ
was shown with the first experiments. When ApoJ was
combined with fixed concentrations of 2% FBS or PDGF-
bb, there was a concentration-dependent decrease in
migration of these stimulated VSMCs. ApoJ (≥ 10
µg/mL) decreased the migration of VSMCs toward 2%
FBS by 96% or more compared with the control (P < .05,
n = 8). In addition, ApoJ (≥ 25 µg/mL) decreased the
migration of VSMCs toward PDGF-bb by 60.9% or more
compared with the control (P < .05, n = 8; Fig 1). By plac-
ing ApoJ in the lower wells, we were concerned that ApoJ
was not being exposed to cells or ApoJ could not pass
freely across the membrane. Placing ApoJ in the upper
wells with the cells produced similar results (not shown).
Fig 1. Effect of ApoJ on migration of VSMCs. ApoJ (1-50
µg/mL) was added to lower wells of microchemotaxis chamber
in combination with DMEM plus 2% FBS (A) or PDGF-bb (10
ng/mL, B), as described in “Material and Methods” section. The
number of cells that migrated was determined microscopically by
counting number of cells per three independent HPFs at magni-
fication of 400×. Data are expressed as mean ± SE (n = 8). *P <
.05 when compared with DMEM plus 2% FBS alone. **P < .01
when compared with DMEM plus 2% FBS alone. †P < .05 when
compared with PDGF-bb alone. ††P < .01 when compared with
PDGF-bb alone.
A
B
Influence of collagen on vascular smooth muscle
cell chemotaxis toward individual growth factors and
apolipoprotein J. To determine whether the influence of
ApoJ on migration resulted from the inability of VSMCs
to bind to the membrane, we initiated chemotaxis experi-
ments with collagen-coated membranes. After cells
attached to the membrane, ApoJ (25 µg/mL) was
aliquoted to the upper wells. The concentration used was
made on the basis of the effects of ApoJ in the earlier assay.
With 2% FBS or PDGF-bb stimulation, ApoJ did not
decrease the migration of attached VSMCs. If VSMCs in
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solution were exposed to ApoJ before application to the
collagen-coated membrane, cell migration toward 2% FBS
or PDGF-bb was decreased by 64% (P < .01, n = 10) or
67.5% (P < .01, n = 10), respectively, compared with the
control (Fig 2). ApoJ, when exposed to VSMCs in solu-
tion, was less effective in decreasing the migration of 2%
FBS-stimulated VSMCs across collagen-coated mem-
branes compared with uncoated membranes (100%
decrease at 25 µg/mL, P < .01; P < .05). ApoJ, when
exposed to VSMCs in solution, was equally effective in
decreasing the migration of PDGF-bb-stimulated VSMCs
across collagen-coated membranes, compared with
uncoated membranes (60.9% decrease at 25 µg/mL, P <
.05; P > .05).
Effect of apolipoprotein J on vascular smooth
muscle cell adhesion to collagen. The ineffectiveness of
ApoJ in decreasing migration of attached VSMCs led us to
postulate that the influence of ApoJ on VSMCs may be
caused in part by the effect of ApoJ on the attachment of
cells in solution to matrix and that decreased migration
was a result of decreased attachment. When ApoJ (25
µg/mL) was exposed to VSMCs attached to collagen, no
statistical difference was seen in cell adhesion compared
with the control. If ApoJ (25 µg/mL) was applied to
VSMCs in solution before plating the cells on collagen,
VSMC adhesion was decreased by 26.8% compared with
the control (P < .01, n = 10; Fig 3). Incubation for longer
times attenuated this effect.
Effect of apolipoprotein J on vascular smooth
muscle cell proliferation. The original intent was to
determine whether ApoJ stimulated VSMC proliferation.
When ApoJ was added to VSMCs resuspended in 0.4%
FBS for 24 hours, it did not stimulate proliferation. ApoJ
Fig 2. Effect of ApoJ on VSMC migration in presence of colla-
gen type I. DMEM plus 2% FBS or PDGF-bb (10 ng/mL) was
added to lower wells of microchemotaxis chamber. ApoJ (25
µg/mL) was exposed to cells 15 minutes before cell application
on collagen membrane (A) or 15 minutes after cell application on
collagen membrane (B), as described in “Material and Methods”
section. The number of cells that migrated was determined
microscopically by counting number of cells per three indepen-
dent HPFs at magnification of 400×. Data are expressed as mean
± SE (n = 10). *P < .01 when compared with DMEM plus 2%
FBS alone or PDGF-bb alone. +, Present; 0, absent.
Fig 3. Effect of ApoJ on VSMC adhesion. ApoJ (25 µg/mL) was
exposed to cells 15 minutes before cell application to collagen
membrane or 15 minutes after cell application to collagen mem-
brane, as described in “Material and Methods” section. The
number of cells attached to upper surface of membrane was deter-
mined microscopically by counting number of cells per three
independent HPFs at magnification of 400×. Data are expressed
as mean ± SE (n = 10). *P < .01 when compared with control.
A
B
decreased thymidine incorporation of VSMCs resus-
pended in 0.4% FBS by 41.1% starting at 25 µg/mL (P <
.05, n = 12). Next, ApoJ was placed in VSMCs resus-
pended in 0.4% FBS and PDGF-bb. ApoJ decreased
thymidine incorporation by 42.8% starting at 50 µg/mL
for ApoJ in PDGF-bb (P < .05, n = 12; Fig 4).
Cytotoxicity of apolipoprotein J. ApoJ-treated cells
had a viability of 68%, compared with 50% for the control
(P < .05, n = 8). ApoJ appeared to increase the viability of
the cells. Similar viability results were obtained with ApoJ
in 0.4% FBS (results not shown). Furthermore, after 3
days in 10% FBS, cell counts were decreased in the ApoJ
samples by 26% compared with the control (P < .05, n =
8), implying decreased cell proliferation (Fig 5). Similar
percent decreases in cell number were seen with 0.4% FBS
and correlated with the thymidine incorporation assay.
Transcriptional profile of vascular smooth muscle
cells exposed to apolipoprotein J. Of the 12,560 genes
screened, 5434 were expressed by ApoJ-treated VSMCs.
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A total of 5092 genes were expressed by the control. A
total of 4592 genes were common to both. Two hundred
seven of these genes had a more than twofold difference in
expression. After analysis, only 30 of the 207 were found
to have true differential expression more than twofold
(Table). The genes with greatest expression in ApoJ-
treated VSMCs were interleukin 8 (IL-8; 4.3-fold) and
endothelin 1 (ET-1; 3.3-fold).
DISCUSSION
This study provides novel insights into the role of
ApoJ in vascular wall biology. The effects of ApoJ on the
migration, adhesion, and proliferation of growth factor-
stimulated VSMCs have not been described. The tran-
scriptional profile of VSMCs exposed to ApoJ fortifies
some of these observations and provides new insights into
its mechanism of action. These results will help explain
why ApoJ is present during tissue injury and tissue remod-
eling and how ApoJ may be involved in cell differentiation
and cytoprotection.
ApoJ is a potent inhibitor of VSMC migration (Figs 1
and 2). The inhibition of ApoJ is effective only with cells in
solution and not with preattached cells (Fig 2). The cell-
aggregating properties of ApoJ may play a role in this
process by making cell-cell contact so strong that chemo-
taxis is not possible. Alternatively, ApoJ may induce a
chemotactic agent in VSMCs to counteract the migratory
gradient set up by FBS or PDGF. Additionally, the effect
seen may, in part, result from competition between ApoJ
and extracellular matrix for the same binding site, facilitat-
ing VSMC adhesion, a precursor to migration (Fig 3).
Because the decrease in adhesion is lower than the
decrease in migration, adhesion may be only one factor
Fig 4. Effect of ApoJ on growth factor-induced proliferation of
VSMCs. VSMCs in DMEM plus 0.4% FBS were incubated with
(A) or without (B) 10 ng/mL PDGF-bb for 24 hours, as
described in “Material and Methods” section. Amount of
[Methyl-3H] thymidine incorporated into cellular DNA was deter-
mined by means of liquid scintillation counting and expressed as
counts per minute (cpm). Values represent the mean ± SE (n =
12). *P < .05; **P < .01 when compared with DMEM plus 0.4%
FBS alone; †P < .05 when compared with PDGF-bb (10 ng/mL)
alone. 10% FBS, Positive control; PBS, negative control.
Fig 5. Cell viability of ApoJ. Cells were incubated for 72 hours
with ApoJ (50 µg/mL) and DMEM plus 10% FBS. Control was
DMEM plus 10% FBS alone. Viability was determined by means
of trypan blue exclusion method, as described in “Material and
Methods” section. Data are expressed as mean ± SE. Percentages
represent cell viability. *P < .01 compared with control B; **P <
.05 compared with control viability. A, Dye-excluded cells; B,
total number of cells (n = 8). 
A
B
contributing to migratory inhibition. Further investiga-
tion is needed to elucidate the mechanism by which
migration is inhibited.
The effect of ApoJ on VSMC adhesion may serve a
regulatory role in the context of tissue injury. Silkensen et
al17 have suggested that in tissue injury and remodeling,
the cell-substratum is disturbed. Cells devoid of a healthy
matrix are more prone to leave the senescent state and
become apoptotic. ApoJ may exist during this early time to
promote cell aggregation and limit apoptosis until mature
cell-substratum attachments can be formed. Furthermore,
the ability of ApoJ to promote cell aggregation may be
dependent on the state of cell-substratum interactions—
that is, its effect is greater when interactions between the
substratum and anchorage-dependent cells are weakest.22
Ongoing studies seek to identify the strength of adhesion
and the effect of ApoJ on cell spreading.
In contrast with the results of this study, Silkensen et
al17 have shown that ApoJ facilitates adhesion. However,
there are several differences between the two studies.
Their investigation used endothelial cells. There may be a
difference in the action of ApoJ on this cell type. Also,
ApoJ was plated onto a surface with matrix, and then cells
were placed onto the ApoJ matrix. In our study, cells were
exposed to ApoJ in solution before plating on a collagen
matrix. Furthermore, the other studies used a much
longer time period, whereas our study was conducted for
1 hour. This longer period may facilitate adhesion as the
cell-matrix interactions become greater and the force of
that interaction with time overcomes the cell-cell interac-
tions caused by ApoJ. Alternatively, ApoJ may activate
other genes involved in cell-matrix adhesion that are
expressed at later times, which might be beneficial when
tissue injury has been repaired. Further investigation is
needed to explore these differences at early and late points
in adhesion.
Another novel finding from this study is that ApoJ
inhibits growth factor-stimulated VSMC proliferation.
This inhibition is supported by decreased thymidine incor-
poration and decreased cell count numbers (Figs 4 and 5).
ApoJ may accomplish inhibition of proliferation by main-
taining the cell in the G0 state. Bettuzzi et al23 showed
that there was a peak in ApoJ mRNA and protein expres-
sion in fibroblasts brought to G0 by means of serum star-
vation.
Because ApoJ inhibits the migration and proliferation
of VSMCs, it may modulate VSMC response in IH by
maintaining VSMC differentiation, senescence, or both.
Thomas-Salgar and Millis16 showed that increased rates of
VSMC nodule formation, a differentiation marker, corre-
late with increased ApoJ mRNA. Furthermore, the onset
of ApoJ mRNA precedes the first signs of nodule forma-
tion. In addition, Moulson and Millis15 demonstrated that
ApoJ has a direct role in phenotypic modulation of
VSMCs and a causal role in nodule formation with
increased smooth muscle α-actin. Thus, our study and the
aforementioned studies, from a functional and morpho-
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logic standpoint, support the hypothesis that ApoJ causes
VSMCs to take on a differentiated phenotype.
This investigation supports the results of earlier stud-
ies about ApoJ and cytoprotection.12,24 Increased viability
of cells exposed to ApoJ was shown by means of the try-
pan blue exclusion. Although trypan blue is a means of
assessing only lethal cytotoxicity, it has been shown by
means of several observations in this and other studies that
ApoJ does not induce nonlethal cytotoxicity. VSMCs
exposed to ApoJ retained their ability to be replated and
subcultured in this study. Humphreys et al24 have shown
that ApoJ protects cells similarly to heat shock proteins.
Schwochau et al12 found that ApoJ protected cells against
nonlethal extracellular and intracellular oxidant stress.
Furthermore, ApoJ at the concentrations studied is not
toxic, because human serum concentrations range from 50
to 340 µg/mL.25 This apparent cytoprotective effect of
ApoJ may be caused by cell aggregation.
This study is the first to show some of the target genes
of ApoJ in VSMCs. Although gene array has traditionally
been applied to RNA extracted from tissues, our study is
not the first to show the usefulness and reliability of this
technique with cell culture.26-28 Of the 30 genes, only IL-
Differentially expressed genes in human aortic vascular
smooth muscle cells exposed to apolipoprotein J for 24
hours
Gene Fold change
Interleukin 8 4.3
Endothelin 1 3.3
β thromboglobulin-like protein 2.7
Interleukin 1-β 2.4
Stanniocalcin precursor 2.1
Melanoma growth stimulatory activity 2.6
Clone DKFZp586E1621 2.1
Cyclooxygenase-2 2.3
Adipogenesis inhibitory factor 3.4
Vacuolar proton ATPase, subunit D 2.4
Putative cyclin G1 interacting protein 2.3
Metalloproteinase stromelysin-2 2.7
Major group rhinovirus receptor 2.1
Integrin α-2 subunit 3.4
Clone IMAGE 2555461 2.1
Clone DKFZp5660133 3.1
Throbomodulin 2.2
Clone DKFZp564A132 2.7
Lysosomal neuraminidase precursor 3.1
EDMD gene 3.1
Keratin 18 –2.4
Fvt 1 2.8
Insulin-like growth factor binding protein 2 2.3
Lung cancer candidate FUS1 3.9
Alcohol dehydrogenase β-1 subunit –2.7
GTP cyclohydrolase 1 2.2
TRAF 5 –2.5
A2b adenosine receptor –2.4
Transcription factor ISGF-3 –2.1
Early growth response 2 protein –2.3
Genes differentially expressed by a more than 2.0-fold in order of descend-
ing expression intensity in ApoJ-exposed VSMCs, among 12,560 genes.
8 and ET-1 will be discussed, because their concomitant
role in vascular lesion formation supports a contributory
role for ApoJ in the results of this study. IL-8 is a cytokine
involved in the inflammatory process, attracting its pri-
mary targets, macrophages and neutrophils. IL-8 from
VSMCs acts on endothelial cells.29 However, IL-8 has
been shown by means of recent evidence to act on VSMCs
as well. IL-8 stimulates VSMC migration and prolifera-
tion.30 This seems contrary to the actions of ApoJ.
However, IL-8 also induces VSMC to produce
prostaglandin E2, which can inhibit IL-8-induced VSMC
proliferation.30 Proliferation in this study is possibly sup-
pressed by prostaglandin production induced by IL-8.
This is supported by the upregulation of cyclooxygenase-
2, a key enzyme in prostaglandin synthesis (Table).
Furthermore, IL-8 produced by VSMCs in the arterial
media may work to decrease the chemotactic gradient
between the intima and media, preventing migration into
the intima. Further investigation is needed to elucidate
ApoJ-induced IL-8 production in VSMCs.
ET-1 is a powerful vasoconstrictor that can be induced
by cytokine stimulation in VSMCs.31 ET-1 has been
shown to cause VSMC differentiation and inhibit apopto-
sis. ET-1 inhibits VSMC proliferation by preventing cell
cycle progression and by decreasing the receptor PDGF-α.
It also induces α-actin. These characteristics suggest a
morphogenic potential for ET-1.32 Besides regulating vas-
cular tone and vascular remodeling, ET-1 inhibits serum
deprivation and nitric oxide-induced apoptosis.33 Thus,
the observations of ApoJ-exposed VSMCs in this study
may, in part, be explained by ET-1 action.
In conclusion, ApoJ is upregulated during IH as early
as 5 days after implantation and is isolated to VSMCs.2
This study clearly demonstrates ApoJ is a potent inhibitor
of VSMC migration, adhesion, and proliferation. The
effects of ApoJ on VSMCs may, in part, be explained by
the upregulation of IL-8 and ET-1. ApoJ may regulate
and influence the early development of IH by promoting
cell differentiation and senescence and inhibiting apopto-
sis. Further investigation is needed to determine how the
gene targets of ApoJ are integrally related in regulating
VSMC function.
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